Benjamin F. Edwards & Company’s Bio-Rad Laboratories Class A BIO Stock Holding History

Benjamin F. Edwards & Company’s Portfolio BIO Stock Details BIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	$14K	Sell	50 -6	-11%	-$1.75K	﹤0.01%	1623
2024 Q1	$19K	Buy	56 +18	+47%	+$5.92K	﹤0.01%	1542
2023 Q4	$12K	Buy	+38	New	+$11.9K	﹤0.01%	1603
2021 Q1	–	Sell	-380	Closed	-$222K	–	1671
2020 Q4	$222K	Hold	380	–	–	0.01%	609
2020 Q3	$196K	Hold	380	–	–	0.01%	594
2020 Q2	$172K	Hold	380	–	–	0.01%	603
2020 Q1	$133K	Hold	380	–	–	0.01%	615
2019 Q4	$141K	Hold	380	–	–	0.01%	695
2019 Q3	$126K	Buy	+380	New	+$124K	0.01%	679
2014 Q1	–	Sell	-18	Closed	-$2K	–	895
2013 Q4	$2K	Buy	+18	New	+$2.19K	﹤0.01%	852

Other funds holding BIO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VAM

Veritas Asset Management London, United Kingdom $5.56B AUM 3.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

VanEck Associates New York $164B AUM 112.45% 1-Year Est. Return

Select Equity Group New York $20.2B AUM 17.52% 1-Year Est. Return

First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Benjamin F. Edwards & Company's BIO Position: Q2 2024 in Review

Benjamin F. Edwards & Company reduced its Bio-Rad Laboratories Class A (BIO) stake by 11% in Q2 2024, selling an estimated $1.75K and leaving 50 shares worth $14K. The position accounts for ﹤0.01% of the portfolio, ranked #1623.

Benjamin F. Edwards & Company first reported a position in BIO in Q4 2013 and has held it in 10 quarters since. The position peaked at $222K in Q4 2020. 440 funds tracked by Wall St. Rank hold BIO as of Q2 2024.

Benjamin F. Edwards & Company held 50 shares of Bio-Rad Laboratories Class A worth $14K as of Q2 2024.
Benjamin F. Edwards & Company sold 6 Bio-Rad Laboratories Class A shares in Q2 2024, an estimated $1.75K.
Bio-Rad Laboratories Class A made up ﹤0.01% of Benjamin F. Edwards & Company's portfolio in Q2 2024, its #1623 holding.
Benjamin F. Edwards & Company first reported a position in Bio-Rad Laboratories Class A in Q4 2013 and has held it in 10 quarters since.
Benjamin F. Edwards & Company's Bio-Rad Laboratories Class A position peaked at $222K in Q4 2020.
440 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2024.

Based on Benjamin F. Edwards & Company's 13F filing for Q2 2024, filed 12 Aug 2024.